US 7,547,524 B2
	Genetically engineered pyrroloquinoline quinone dependent glucose dehydrogenase comprising an amino acid insertion
Mara Boenitz-Dulat, Tutzing (Germany); Jessica Laggerbauer, München (Germany); Rainer Schmuck, Benediktbeuern (Germany); Peter Kratzsch, Penzberg (Germany); and Wolfgang-Reinhold Knappe, Ludwigshafen (Germany)
Assigned to Roche Diagnostics Operations, Inc., Indianapolis, Ind. (US)
Appl. No. 11/632,672 PCT Filed Jul. 19, 2005, PCT No. PCT/EP2005/007844 § 371(c)(1), (2), (4) Date Jan. 17, 2007, PCT Pub. No. WO2006/008132, PCT Pub. Date Jan. 26, 2006.
Claims priority of application No. 04017069 (EP), filed on Jul. 20, 2004.
Prior Publication US 2007/0243566 A1, Oct. 18, 2007
Int. Cl. C12Q 1/32 (2006.01); C12N 9/02 (2006.01)

U.S. Cl. 435—26  [435/189]

13 Claims

1. A variant of PQQ-dependent soluble glucose dehydrogenase (s-GDH), said variant comprising the sequence of SEQ ID NO: 2 modified by the insertion of one amino acid residue between the amino acid positions corresponding to positions 428 and 429 of the s-GDH wild-type sequence known from A. calcoaceticus(SEQ ID NO: 2), a substitution of threonine at position 348 of SEQ ID NO: 2 with an amino acid residue selected from the group consisting of alanine, glycine and serine, and optionally, one or more additional amino acid substitutions, wherein said variant is at least 90% identical to SEQ ID NO: 2 , and has s-GDH activity.